1 / 10Sheela Foam | The maker of popular mattress brand Sleepwell is gearing up for a significant capital infusion by launching a Qualified Institutional Placement (QIP) to raise funds amounting to Rs 1,200 crore. The QIP's base size has been set at Rs 1,000 crore, with an additional upsize option of Rs 200 crore.
2 / 10Zydus | Zydus has received final approval from the USFDA for Clindamycin Phosphate Gel USP, 1%. Clindamycin Phosphate gel is used to treat acne.
3 / 10SJVN | The government plans on divesting up to 4.92 percent stake in hydroelectric power generator via an Offer for Sale, an exchange filing stated. The base offer will be to sell up to 9.66 crore shares or 2.46 percent of the total equity with a green shoe option to sell another 9.66 crore shares or 2.46 percent of the total equity.
4 / 10Apollo Tyres | Tyre manufacturer on Wednesday announced the temporary cessation of bias off-the-road (OTR) tyre production at its manufacturing facility located in Limda, Gujarat. The decision was prompted by concerns raised among shop floor employees regarding the renewal of a long-term settlement agreement, according to a stock exchange filing.
5 / 10Kalpataru Projects | The firm will consider fund raising via NCDs on private placement basis on September 25.
6 / 10West Coast Paper Mills | The company on Wednesday said it has received preliminary verbal approval from the National Company Law Tribunal, Chennai Bench, for its resolution plan submitted to acquire Uniply Décor Ltd. Currently, Uniply Décor Ltd is undergoing a Corporate Insolvency Resolution Process under the provisions of the Insolvency and Bankruptcy Code, 2016.
7 / 10Cipla | Drug firm on Wednesday said the United States Food and Drug Administration (USFDA) recently carried out an inspection at the manufacturing facility of InvaGen Pharmaceuticals Inc, a wholly-owned subsidiary of the company. The facility is located in Central Islip, Long Island, New York, USA, and the inspection took place from September 11 to September 19, 2023.
8 / 10Zydus Lifesciences | Drug firm on Wednesday said it has achieved a significant milestone on getting final approval from the United States Food and Drug Administration for its clindamycin phosphate gel USP, 1. Clindamycin phosphate gel USP, 1% serves as a crucial treatment for acne, playing a pivotal role in reducing the number of acne lesions.
9 / 10Biocon | In a significant milestone, Biocon Biologics Ltd, a subsidiary of Biocon, on Wednesday announced the granting of marketing authorisation by the European Commission for YESAFILI, a biosimilar of aflibercept. This decision by the EC follows the positive opinion conveyed by the European Medicines Agency's Committee for Medicinal Products for Human Use in July.
10 / 10Coal India | State-run on Wednesday said it has been served a three-day strike notice by central trade unions. The joint strike notice, issued jointly by the prominent labour organisations BMS, INTUC, HMS, AITUC, and CITU, has set the stage for a three-day strike commencing on October 5 and lasting until October 7, 2023.
